An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma

Experimental Cell Research

Volumn 319, Issue 5, 2013, Pages 600-611

  Lin, Huiqiong ^a,b   Kolosenko, Iryna ^a   Björklund, Ann Charlotte ^a   Protsyuk, Darya ^a   Österborg, Anders ^a   Grandér, Dan ^a   Tamm, Katja Pokrovskaja ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

17DMAG; Akt; Apoptosis; HSP90; Multiple myeloma; STAT3

Indexed keywords

CASPASE 3; CD45 ANTIGEN; HEAT SHOCK PROTEIN 90; INTERLEUKIN 6; JANUS KINASE; MESSENGER RNA; PROTEIN MCL 1; STAT3 PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RECURRENCE; CELL SUBPOPULATION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; DNA BINDING; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84873987471     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.12.006     Document Type: Article

References (34)

1. Hideshima T., Mitsiades C., Tonon G., Richardson P.G., Anderson K.C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. Cancer 2007, 7:585-598.
2. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., Kuramoto A., Kishimoto T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988, 332:83-85.
3. Frassanito M.A., Cusmai A., Iodice G., Dammacco F. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 2001, 97:483-489.
4. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernandez-Luna J.L., Nunez G., Dalton W.S., Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
5. Hideshima T., Catley L., Raje N., Chauhan D., Podar K., Mitsiades C., Tai Y.T., Vallet S., Kiziltepe T., Ocio E., Ikeda H., Okawa Y., Hideshima H., Munshi N.C., Yasui H., Richardson P.G., Anderson K.C. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br. J. Haematol. 2007, 138:783-791.
6. Zhang J., Choi Y., Mavromatis B., Lichtenstein A., Li W. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway. Oncogene 2003, 22:6289-6295.
7. Richardson P.G., Mitsiades C.S., Laubach J.P., Lonial S., Chanan-Khan A.A., Anderson K.C. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br. J. Haematol. 2011, 152:367-379.
8. Stuhmer T., Zollinger A., Siegmund D., Chatterjee M., Grella E., Knop S., Kortum M., Unzicker C., Jensen M.R., Quadt C., Chene P., Schoepfer J., Garcia-Echeverria C., Einsele H., Wajant H., Bargou R.C. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia 2008, 22:1604-1612.
9. Zollinger A., Stuhmer T., Chatterjee M., Gattenlohner S., Haralambieva E., Muller-Hermelink H.K., Andrulis M., Greiner A., Wesemeier C., Rath J.C., Einsele H., Bargou R.C. Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood 2008, 112:3403-3411.
10. Descamps G., Pellat-Deceunynck C., Szpak Y., Bataille R., Robillard N., Amiot M. The magnitude of Akt/phosphatidylinositol 3'-kinase proliferating signaling is related to CD45 expression in human myeloma cells. J. Immunol. 2004, 173:4953-4959.
11. Ishikawa H., Tsuyama N., Abroun S., Liu S., Li F.J., Taniguchi O., Kawano M.M. Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6. Blood 2002, 99:2172-2178.
12. Descamps G., Wuilleme-Toumi S., Trichet V., Venot C., Debussche L., Hercend T., Collette M., Robillard N., Bataille R., Amiot M. CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642. J. Immunol. 2006, 177:4218-4223.
13. + myeloma cells. Am. J. Hematol. 2010, 85:675-686.
14. Nilsson K., Bennich H., Johansson S.G., Ponten J. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin. Exp. Immunol. 1970, 7:477-489.
15. Thyrell L., Arulampalam V., Hjortsberg L., Farnebo M., Grander D., Pokrovskaja Tamm K. Interferon alpha induces cell death through interference with interleukin 6 signaling and inhibition of STAT3 activity. Exp. Cell Res. 2007, 313:4015-4024.
16. Burger R., Guenther A., Bakker F., Schmalzing M., Bernand S., Baum W., Duerr B., Hocke G.M., Steininger H., Gebhart E., Gramatzki M. Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematol. J. 2001, 2:42-53.
17. Pedranzini L., Dechow T., Berishaj M., Comenzo R., Zhou P., Azare J., Bornmann W., Bromberg J. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res. 2006, 66:9714-9721.
18. Thyrell L., Hjortsberg L., Arulampalam V., Panaretakis T., Uhles S., Dagnell M., Zhivotovsky B., Leibiger I., Grander D., Pokrovskaja K. Interferon alpha-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway. J. Biol. Chem. 2004, 279:24152-24162.
19. Greipp P.R., San Miguel J., Durie B.G., Crowley J.J., Barlogie B., Blade J., Boccadoro M., Child J.A., Avet-Loiseau H., Kyle R.A., Lahuerta J.J., Ludwig H., Morgan G., Powles R., Shimizu K., Shustik C., Sonneveld P., Tosi P., Turesson I., Westin J. International staging system for multiple myeloma. J. Clin. Oncol. 2005, 23:3412-3420.
20. Irish J.M., Myklebust J.H., Alizadeh A.A., Houot R., Sharman J.P., Czerwinski D.K., Nolan G.P., Levy R. B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc. Nat. Acad. Sci. U.S.A. 2010, 107:12747-12754.
21. Arulampalam V., Kolosenko I., Hjortsberg L., Bjorklund A.C., Grander D., Tamm K.P. Activation of STAT1 is required for interferon-alpha-mediated cell death. Exp. Cell. Res. 2011, 317:9-19.
22. Duus J., Bahar H.I., Venkataraman G., Ozpuyan F., Izban K.F., Al-Masri H., Maududi T., Toor A., Alkan S. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma. Leuk. Lymphoma 2006, 47:1369-1378.
23. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Kung A.L., Davies F.E., Morgan G., Akiyama M., Shringarpure R., Munshi N.C., Richardson P.G., Hideshima T., Chauhan D., Gu X., Bailey C., Joseph M., Libermann T.A., Rosen N.S., Anderson K.C. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006, 107:1092-1100.
24. Chatterjee M., Jain S., Stuhmer T., Andrulis M., Ungethum U., Kuban R.J., Lorentz H., Bommert K., Topp M., Kramer D., Muller-Hermelink H.K., Einsele H., Greiner A., Bargou R.C. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 2007, 109:720-728.
25. Bataille R., Robillard N., Pellat-Deceunynck C., Amiot M. A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy. Immunol. Rev. 2003, 194:105-111.
26. Collette M., Descamps G., Pellat-Deceunynck C., Bataille R., Amiot M. Crucial role of phosphatase CD45 in determining signaling and proliferation of human myeloma cells. Eur. Cytokine Netw. 2007, 18:120-126.
27. Pellat-Deceunynck C., Bataille R. Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. Blood Cells Mol. Dis. 2004, 32:293-301.
28. Kumar S., Rajkumar S.V., Kimlinger T., Greipp P.R., Witzig T.E. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia 2005, 19:1466-1470.
29. Isomoto H., Kobayashi S., Werneburg N.W., Bronk S.F., Guicciardi M.E., Frank D.A., Gores G.J. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005, 42:1329-1338.
30. Jourdan M., Veyrune J.L., De Vos J., Redal N., Couderc G., Klein B. A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 2003, 22:2950-2959.
31. Panaretakis T., Pokrovskaja K., Shoshan M.C., Grander D. Interferon-alpha-induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax. Oncogene 2003, 22:4543-4556.
32. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., Darnell J.E. Stat3 as an oncogene. Cell 1999, 98:295-303.
33. Pene F., Claessens Y.E., Muller O., Viguie F., Mayeux P., Dreyfus F., Lacombe C., Bouscary D. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002, 21:6587-6597.
34. Liu S., Ishikawa H., Tsuyama N., Li F.J., Abroun S., Otsuyama K.I., Zheng X., Ma Z., Maki Y., Iqbal M.S., Obata M., Kawano M.M. Increased susceptibility to apoptosis in CD45(+) myeloma cells accompanied by the increased expression of VDAC1. Oncogene 2006, 25:419-429.